Gain insights from a Clinical Trials Global Regulatory Lead on navigating the evolving global regulatory landscape, from early development through to submission readiness.
- Anticipating regulatory expectations and aligning strategies early in development
- Integrating regulatory perspectives across Phase I–III to streamline approvals
- Common challenges and proactive approaches in global filing preparation
Why the oversight of CROs need an evolution
- Transforming Role of the CRO: from vendor to strategic allies
- Changing mindset from sponsor holds risks to sharing risk approach
- Implementing the change in various types of trials
The cards are already on the table. The question is whether Europe knows how to play them. This session explores how the EU can turn global uncertainty into a defining moment for clinical research, manufacturing and R&D leadership.
- Closing the gap with the USA and China: accelerating decision timelines, unlocking translational funding and giving NCA alignment real teeth across all 27 member states.
- Turning US instability into EU opportunity: how NIH cuts, FDA uncertainty and policy unpredictability are opening a window for EU-first trial strategies and how long it may stay open.
- Making regulatory alignment stick: from ICH harmonization to more effective collaboration building a system where alignment is enforced, not just encouraged.
